Education

2013-2017  Yale-New Haven Hospital, New Haven, CT; Resident and Chief Resident, Radiation Oncology

2015-2016 Yale Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine, New Haven, CT; Auditor

2012-2013 Yale- New Haven Hospital, New Haven, CT; Intern, Internal Medicine

2007-2012 University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; M.D.

2002-2006 Brown University, Providence, RI; Sc. B, Honors, Neuroscience

Academic Appointments

Assistant Professor of Radiation Oncology (2017-present)

Clinical Appointments

Radiation Oncology, University of Vermont Medical Center (2017-present)

Committee Appointments

Institutional Review Board, Committee on Human Research in the Medical Science,  Member (2017-present)

College of Medicine Committee on Admissions, Member (2019-present)

American Society for Radiation Oncology (ASTRO) Promoting Science through Research and Training Committee, 2018-present

Awards and Honors

2019 Outstanding Reviewer Award, International Journal of Radiation Oncology, Biology, Physics

2017 Outstanding Reviewer Award, International Journal of Radiation Oncology, Biology, Physics

2016-2017 Chief Resident, Radiation Oncology, Yale-New Haven Hospital

2016 Best of ASTRO Abstract Award, 2016 ASTRO Annual Meeting

2012 Scientific Abstract/Travel ASTRO Award, 2012 ASTRO Annual Meeting

2012 Abramson Cancer Center Clinical Research Prize, University of Pennsylvania

2011 Susan G. Komen AACR Scholar-in-Training Award, San Antonio Breast Care Symposium

2008 Paul D. Stolley Research Award, University of Pennsylvania

2006 Sigma Xi Scientific Honors Research Society, Brown University

2003 Undergraduate Teaching and Research Award, Brown University

Membership

2013-present Member of American Society for Radiation Oncology (ASTRO)

2013-present Member of American Society of Clinical Oncology

2018-present Member of International Association for the Study of Lung Cancer

2019-present Editorial Board Member (Associate Senior Editor) of Advances in Radiation Oncology 

2019-present Member of Society for Medical Decision Making

Research

Dr. Lester-Coll's research centers on health outcomes and comparative effectiveness of cancer treatments. His work involves complex decision analysis, computational modeling and cost-utility analysis, which are directly relevant to the current healthcare climate and controversies regarding emerging cancer therapies. Dr. Lester-Coll employs these techniques in combination with analyses of large population databases, such as the National Cancer Data Base and SEER-Medicare, to determine the optimal courses of therapy for patients based on the relative cost, effectiveness and impact on quality of life.

Publications

Lester-Coll NH, Rutter CE, Bledsoe TB, Goldberg SB, Decker RH, Yu JB. Cost-Effectiveness of Surgery, Stereotactic Body Radiotherapy and Systemic Therapy for Pulmonary Oligometastases. Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):663-72. PMID 27055395

Lester-Coll NH, Park HS, Rutter CE, Corso CD, Mancini BR, Yeboa DN, Kim SP, Gross CP, Yu JB. The Association Between Evaluation at Academic Centers and the Likelihood of Expectant Management in Low-Risk Prostate Cancer. Urology. 2016 Oct;96:128-135. PMID 27392652

Lester-Coll NH, Dosoretz AP, Magnuson WJ, Laurans MS, Chiang VC, Yu JB. Cost-effectiveness of stereotactic radiosurgery versus whole brain radiation therapy for up to 10 brain metastases. J Neurosurg. 2016 Dec;125(Suppl 1):18-25. PMID 27903191

Lester-Coll NH, Johnson S, Magnuson WJ, Goldhaber SZ, Sher DJ, D’Amico AV, Yu JB. Weighing Risk of Cardiovascular Mortality against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. J Natl Cancer Inst. 2016 Dec 31;109 (6). pii: djw281. PMID 27903191

Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD, Camidge DR, Braunstein SE, Boreta LC, Balasubramanian SK, Ahluwalia MS, Rana NG, Attia A, Gettinger SN, Contessa JN, Yu JB, Chiang VL.Management of Brain Metastases in TKI-naïve EGFR-mutant NSCLC: A Multi-Institutional Analysis. J Clin Oncol. 2017 Apr 1;35(10):1070-1077. PMID 28113019

Johnson SB, Lester-Coll NH, Kelly JR, Kann BH, Yu JB, Nath SK. Brachytherapy Boost Utilization in Unfavorable Risk Prostate Cancer and Survival Implications. Eur Urol. 2017 Nov;72(5):738-744.

3Nicoli CD, Sprague BL, Anker CJ, Lester-Coll NH. Association of Rurality With Survival and Guidelines-Concordant Management in Early-stage Non-Small Cell Lung Cancer. Am J Clin Oncol. 2019 Jul;42(7):607-614.

For a complete list of Dr. Lester-Coll's publications, please visit PubMed
https://www.ncbi.nlm.nih.gov/pubmed/?term=lester-coll